- Summary
- Price Reports
- Price History
- Add To Your Stocklist
- View your Stocklist
- Basic Chart
- Interactive Chart
- Headlines
- Company Snapshot
- Summary Reports
- Free Annual Report
- Estimate Snapshot
- Estimate Report
- Mobile Quote
- Real-Time Quote
- Streaming Quote
|
Genvec, Inc. | Company Snapshot
-
![]()
-
-
-
Vol:
-
Last Trade:
|
GENVEC, INC.
GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade is currently in a pivotal Phase II/III study in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and metastatic melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu, and foot-and-mouth disease.
|
|
| Symbol: |
GNVC |
| Exchange(s): |
Nasdaq Stock Market |
| Industry: |
Consumer Products (Biotechnology & Pharmaceuticals) |
| 5-Star Rating: |
 |
|
ANNUAL FINANCIALS
|
|
|
Dec 31, 2008
12 Months
us$
|
Dec 31, 2007
12 Months
us$
|
Dec 31, 2006
12 Months
us$
|
3Yr.
Growth
% Change
|
|
Total Revenue ($000)
|
15,120
|
14,040
|
18,920
|
-17.11
|
|
Earnings before Interest & Tax ($000)
|
-26,180
|
-18,700
|
-19,030
|
N/A
|
|
Profit/Loss ($000)
|
-26,060
|
-18,700
|
-19,270
|
N/A
|
|
Earnings per Share
|
-0.32
|
-0.25
|
-0.30
|
N/A
|
|
Total Assets ($000)
|
22,760
|
28,340
|
40,160
|
-18.41
|
|
Dividends Per Share
|
0.00
|
0.00
|
0.00
|
|
|
Return on Com. Equity
|
-167.05
|
-76.48
|
-61.95
|
|
|
Employees
|
N/A
|
N/A
|
N/A
|
|
|
|
|
|
Trailing 12 Month Results
|
|
|
12 Months ended
Dec 31, 2009,us$
|
12 Months ended
Dec 31, 2008,us$
|
%Change
|
|
Total Revenue ($000)
|
N/A
|
15,110
|
N/A
|
|
Profit/Loss ($000)
|
N/A
|
-26,060
|
N/A
|
|
Earnings per Share
|
N/A
|
-0.31
|
N/A
|
|
Dividends Per Share
|
0.00
|
0.00
|
|
Number of Shares
|
106,340,000
|
88,420,000
|
|
|
|
|
|
COMPANY INFORMATION
|
| Key Personnel |
| CEO: Paul H. Fischer Ph.D., Presi.; C.E.O.; Dir. |
| CFO: Mark O. Thornton Ph.D., Sr. V.P.; Product Devlopt. |
| |
| Contact Information |
| Address: |
65 West Watkins Mill Road,
Gaithersburg,
MD,
20878 |
Phone: |
240-632-0740 |
| Fax: |
240-632-0735 |
| Web Address: |
www.genvec.com |
| |
| |
| Incorporation:
| United States |
| |
|
Securities:
|
GNVC-Q
|
|
| |
|
|
| |
|
|
Financial data is provided by Zacks Investment Research.
| |
All information on this site is compiled by CTVglobemedia Publishing Inc. from reliable industry sources. While all efforts are made to ensure the accuracy of the information, CTVglobemedia Publishing Inc. and its related entities assume no liability for incorrect, incomplete, or missing information from this site. Past performance is not necessarily indicative of future performance. Prior to making any investment decision, consult with a qualified investment advisor.
Copyright © 2010 CTVglobemedia Publishing Inc. All rights reserved.
|
|
|
